CoChat

Belantamab Mafodotin: First Approval

Markham, Anthony · 2020 · Drugs

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Belantamab mafodotin (BLENREP ™ ; belantamab mafodotin-blmf) is a first-in-class monoclonal antibody-drug conjugate (ADC) that has been developed for the treatment of multiple myeloma by GlaxoSmithKline. The ADC comprises an antibody targeting B-cell maturation antigen (BCMA) conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). The antibody moiety binds to BCMA on the tumour cell surface, delivering the cytotoxic microtubule inhibitor MMAF to the therapeutic target. Based on preliminary results from the multinational DREAMM-2 trial, belantamab mafodotin was approved in early August 2020 in the USA for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies, including an anti CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The ADC was also approved in the EU for this indication in late August 2020. This article summarizes the milestones in the development of belantamab mafodotin leading to this first approval.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-020-01404-x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Cited by

See all 145

Metadata

Authors
Markham, A.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Markham, Anthony
Venue
Drugs
Published
2020-09-16
Volume
80
Issue
15
Pages
1607-1613
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3087214205
Cited by
145
References
7
Citations by year
2026: 8 · 2025: 19 · 2024: 34 · 2023: 22 · 2022: 30 · 2021: 29 · 2020: 3
FWCI
13.25
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
belantamab mafodotin, antibody-drug conjugates, multiple myeloma, BCMA, monomethyl auristatin F, relapsed/refractory multiple myeloma, drug approval, microtubule inhibitors
MeSH terms
Progression-Free Survival, Adult, Animals, Clinical Trials as Topic, Humans, Infusions, Intravenous, Multiple Myeloma, Neoplasm Recurrence, Local, Neoplasm Staging, Oligopeptides, Drug Approval, Disease Progression, Immunoconjugates, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Tubulin Modulators, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Belantamab Mafodotin: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01404-x
The paper
Markham, A. (2020). Belantamab Mafodotin: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01404-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.